Trump Fast-Tracks Psychedelic Drug Research

On April 18, President Trump just signed an executive order pushing his administration

to fast-track reviews for psychedelic drugs like IboGain, AEboGain.

Substance vets in some conservatives are hyping for treating tough issues like PTSD and opioid addiction.

Right now, IboGain sits in the stricter federal ban category as a high-risk schedule one drug,

but Trump wants to speed up research and access after.

regulators flagged it as a potential breakthrough.

The Food and Drug Administration steps up next week with national priority vouchers for

three psychedelics, the first time ever for this class of.

Drugs, letting them skip lines if they match key health goals.

They're also paving the way for the very first human trials of IBILGAME right here in

the United States.

Vets groups and advocates have pushed hard for this, saying IBILGAME from a West African

plant could change lives, and it's getting rare by partisan.

Backing, including from Health Secretary Robert F. Kennedy, Jr.

One vet told Trump it saved his life during the signing ceremony.

Even with the buzz, experts note serious heart risks, like your regular rhythms linked

to over 30 deaths in studies, which halted U.S. research back.

In the 1990s, a small Stanford study on 30 vets treated in Mexico showed gains in PTSD,

depression, and anxiety symptoms, but lacked a placebo control.

This move puts IBILGAME on the federal radar, shifting it from underground clinics abroad

to a legit science, though no insurance coverage or quick.

Approvals yet could spark more state-level research soon.

National News, powered by AI, this is U.S. News Today.